New Haven, Conn., Nov. 11, 2026 Globe Newswire -- Arvinas, Inc. Nasdaq ARVN , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management wi
Arvinas, Inc (ARVN) — Live Session & Technical Brief
Updated Nov 16, 2026 2:50 PM ET · Prev Close $6.82
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-1.17%) in Biotechnology
Arvinas, Inc (ARVN) is trading within a tight intraday band at $6.74 (-1.17%, 0.96x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ARVN is outperforming the S&P 500 by +0.81%. 14-day RSI stands at 41.7, keeping momentum in a bearish regime.
New Haven, Conn., Nov. 11, 2026 Globe Newswire -- Arvinas, Inc. Nasdaq ARVN , a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management wi
Price ($6.74) trades relative to 20-day SMA ($7.22) and 50-day SMA ($7.57).
Market & Sector Relative Strength
ARVN outperforming the S&P 500 by +0.81%Recent ARVN Catalyst Headlines
Verified WireData presentation to include safety, pharmacokinetics PK , and pharmacodynamics PD from all patients, with preliminary efficacy from patients with T-cell lymphomas, in patients with relapsed refractory non-Hodgkin lympho
Arvinas shocked the market with its latest quarterly filing, reporting Q2 2026 revenue of US 249.7 million and net income of US 169.4 million, a sharp shift from losses a year earlier, yet the share chart tells a differe
Moby summary of Arvinas, Inc.'s Q3 2026 earnings call
1–3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $7.22 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (ARVN)
BEARISH MA TRENDRetail & Crowd Sentiment
BullishArvinas is presenting preliminary clinical data from the Phase 1 study of Arv-393 (zaloblideg), an oral Protac BCL6 degrader, at the 2026 American Society of Hematology (ASH) Annual Meeting. The data will include safety, pharmacokinetics, and pharmacodynamics from all patients, with preliminary efficacy from patients with T-cell lymphomas.
About Arvinas, Inc
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (Protac), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The …
Get Instant ARVN Catalyst Alerts
Receive an email alert when ARVN triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversARVN Session & Catalyst FAQ
Why is ARVN stock trading near flat today?
Arvinas, Inc (ARVN) is trading within a tight intraday band at $6.74 (-1.17%, 0.96x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, ARVN is outperforming the S&P 500 by +0.81%. 14-day RSI stands at 41.7, keeping momentum in a bearish regime.
Is ARVN stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.96x relative volume (moderate participation). Our multi-factor model currently rates ARVN as HOLD. Review full valuation, quality, and timing signals on the ARVN Buy or Sell Decision Brief →
What is ARVN's intrinsic value and expected trading range?
At $6.74, ARVN's modeled 1-to-3 session range is $6.51 – $6.97, with a key inflection level at $7.22 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the ARVN Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for ARVN?
RSI at 41.7 reflects soft below-midline momentum. ARVN trades at $6.74 relative to its 20-day SMA ($7.22) and 50-day SMA ($7.57), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.